MedTrace Logo

Sentinel Lymph Node Biopsy in Patients With Breast Cancer After Neoadjuvant Therapy

NCT03556397 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2021-02-18

No results posted yet for this study

Summary

The aim of this study is to create clear indications for Sentinel Lymph Node Biopsy (SLNB) or Axillary Dissection (AD) in women with breast carcinoma after neoadjuvant therapy by studying the false negative rate of SLNB.

Conditions

Interventions

PROCEDURE

Sentinel lymph node biopsy (SLNB)

Sentinel lymph node biopsy will be performed in the patients

PROCEDURE

Axillary dissection

Axillary dissection procedure will be performed in the patients

Sponsors & Collaborators

  • Silesian Hospital in Opava

    collaborator OTHER

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Jan Žatecký, MD · Silesian Hospital in Opava

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03556397 on ClinicalTrials.gov